Scholarlink

<p>Front-line treatment with all-trans retinoic acid (ATRA) and arsenic trioxide (ATO) is superior to standard ATRA and chemotherapy (CHT) in patients with low-/intermediate-risk acute promyelocytic leukemia (APL). However, for high-risk (HR) patients (defined as those with a white blood cell count ≥ 10×10⁹/L), the role of ATRA-ATO is subject to debate, and study data are scarce. The objective for the present real-world cohort study was to assess the outcomes in 135 HR APL patients treated with ATRA-CHT or ATRA-ATO during induction at 12 French hospitals between 2010 and 2021. Of the 135 patients, 50 (37%) received ATRA-ATO as induction therapy (though combination with cytoreductive treatment was usually necessary), and 85 received standard ATRA-CHT (“CHT group”). The complete response rates were 90% in the ATRA-ATO group and 76% in the CHT group (<i>p</i> = 0.052). The five-year overall survival (OS) rate was significantly higher in the ATRA-ATO group (89.86% [95% confidence interval: 81.81–98.70]) than in the CHT group (72.69% [63.30–83.47]; <i>p</i> = 0.035). The combination of ATRA and ATO was effective and safe in this large, real-world cohort of HR APL patients. The forthcoming results of the APOLLO trial (a direct comparison of ATRA-ATO with ATRA-CHT) might validate our present findings.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Comparison of induction with arsenic trioxide or chemotherapy in a real-world cohort of patients with high-risk acute promyelocytic leukemia

  • 期刊论文

  • 发表日期：

    2025年6月24日

查看全文
  • Delphine Lebon,
  • Audrey Da Rocha,
  • Bruno Cassinat,
  • Maël Heiblig,
  • Sarah Bertoli,
  • Caroline Bonmati,
  • Anne Zilliox,
  • Marie Laloi,
  • Céline Berthon,
  • Nicolas Duployez,
  • Christophe Willekens,
  • Maria Pilar Gallego Hernanz,
  • Marlène Ochmann,
  • Thomas Cluzeau,
  • Fatiha Chermat,
  • Alexis Caulier,
  • Christian Récher,
  • Mathilde Hunault-Berger,
  • Emmanuel Raffoux,
  • Pierre Fenaux,
  • Jean Pierre Marolleau,
  • Lionel Adès

摘要

Front-line treatment with all-trans retinoic acid (ATRA) and arsenic trioxide (ATO) is superior to standard ATRA and chemotherapy (CHT) in patients with low-/intermediate-risk acute promyelocytic leukemia (APL). However, for high-risk (HR) patients (defined as those with a white blood cell count ≥ 10×10⁹/L), the role of ATRA-ATO is subject to debate, and study data are scarce. The objective for the present real-world cohort study was to assess the outcomes in 135 HR APL patients treated with ATRA-CHT or ATRA-ATO during induction at 12 French hospitals between 2010 and 2021. Of the 135 patients, 50 (37%) received ATRA-ATO as induction therapy (though combination with cytoreductive treatment was usually necessary), and 85 received standard ATRA-CHT (“CHT group”). The complete response rates were 90% in the ATRA-ATO group and 76% in the CHT group (p = 0.052). The five-year overall survival (OS) rate was significantly higher in the ATRA-ATO group (89.86% [95% confidence interval: 81.81–98.70]) than in the CHT group (72.69% [63.30–83.47]; p = 0.035). The combination of ATRA and ATO was effective and safe in this large, real-world cohort of HR APL patients. The forthcoming results of the APOLLO trial (a direct comparison of ATRA-ATO with ATRA-CHT) might validate our present findings.